Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...

A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later ...

Genentech, owned by Roche, has announced new clinical and real-world data for Ocrevus (ocrelizumab) for the treatment of patients with relapsing multiple sclerosis (RMS) or primary progressive ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Natalizumab (Tysabri) and ocrelizumab (Ocrevus) are options if other drugs don't work for you. Natalizumab prevents immune cells from getting to your brain and spinal cord, where they can damage ...

Credit: Genentech Ocrevus Zunovo is supplied in a single-dose vial containing 920mg of ocrelizumab and 23,000 units hyaluronidase per 23mL. Ocrevus Zunovo is a combination of ocrelizumab ...

Roche said regulatory review of this drug is ongoing in additional markets. FDA approval of the MS drug, Ocrevus Zunovo, came the day after the cancer drug approval. Like infused Ocrevus ...

(RTTNews) - Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of ...

The treatment, called Ocrevus Zunovo, was approved as a biannual, approximately 10-minute, under-the-skin injection for patients with relapsing multiple sclerosis and primary progressive multiple ...